Scinai Immunotherapeutics (SCNI) Depreciation & Amortization (CF) (2018 - 2026)

Scinai Immunotherapeutics has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $453000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 29.06% year-over-year to $453000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 37.26% YoY) and the FY2025 annual result came in at $1.4 million, down 13.83% from the prior year.
• Depreciation & Amortization (CF) rose to $453000.0 in Q1 2026 per SCNI's latest filing, from $353000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $499000.0 in Q4 2024 and troughed at $84000.0 in Q4 2023.
• A 5-year average of $258800.0 and a median of $156000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) sank 83.82% in 2022, then soared 494.05% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $184000.0 in 2022, then tumbled by 54.35% to $84000.0 in 2023, then jumped by 494.05% to $499000.0 in 2024, then declined by 29.26% to $353000.0 in 2025, then grew by 28.33% to $453000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $453000.0, $353000.0, and $351000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.